Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
COMMENTARY Filing for Sakigake Radiation Therapy Expected This Year for Head and Neck Cancer; Expanded Use, Overseas Development Eyed
June 25, 2019
-
BUSINESS ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
-
REGULATORY Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
-
TRENDS 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
REGULATORY MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
-
REGULATORY Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
-
TRENDS Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
ORGANIZATION Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
-
BUSINESS Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
-
REGULATORY Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
-
BUSINESS Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
-
BUSINESS Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
-
REGULATORY MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019
-
BUSINESS Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
-
BUSINESS Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
-
ORGANIZATION Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
-
ORGANIZATION Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
-
REGULATORY Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
-
BUSINESS Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
-
REGULATORY June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
May 31, 2019
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…